FreeStyle Libre

Discussion in 'Abbott' started by Anonymous, Oct 25, 2014 at 5:44 PM.

Tags: Add Tags
  1. anonymous

    anonymous Guest

    As I said (above) Libre is a cash cow for Abbott. Luv the stuff.
     

  2. anonymous

    anonymous Guest

    ADC fired you because you were stupid; your statement is incontestable proof ADC was wrong. You are not stupid. You are lack the mental awareness needed to be stupid. Stupid requires some level of intelligence. Just at the low end of the scale. You are somewhere lower than that. Developmentally challenged, mentally handicapped, I'm not sure. Just a simpleton? Regardless, we all owe you an apology. Business terms, even simple math, are beyond your capacity. We have been trying to educate you, but in reality we should just be polite and ignore you. Are there some meds you are supposed to be taking?
     
  3. I left because the pay was very poor. I mean minimum wage for all those lousy meetings is pretty lame. I need a better agent. Remember that a turtle moves faster than a cheetah or Miles after a meeting.
     
  4. anonymous

    anonymous Guest

    I respect you as a Senior DM, that's a lofty position.....but I totally disagree with your post. ADC has many great managers and they know EXACTLY what they are doing. You may have been fed a line of shxt from your regional leaders. They typically however, are poor communicators - that may explain your post.
     
  5. anonymous

    anonymous Guest


    ADC make a deal with Google ? Doubtful that was ever possible however much MW wanted it. The reason being, Google are not fools. They see Libre for a what it is - a low volume trial with high manufacturing costs, using 10 year old technology, with no successor products planned.

    Dexcom by contrast have multiple CGM products in development, as the article makes clear. Google's choice of partner was entirely logical.

    However, Google's record on medical devices has been poor so far, mainly because they don't understand how the regulatory process works. For example, the FDA banned Google's new genetic test product in 2012. Therefore they probably won't win the cheap CGM race - but their participation will encourage others to come forward. Everyone knows that if Google decide to compete in a market, the prize for the winner must be large.
     
  6. anonymous

    anonymous Guest

    Minimum wage? Makes sense ... Libra boy emptied the trash cans, or work in the cafeteria. All makes sense now.
     
  7. anonymous

    anonymous Guest

    IMO You are BOTH A-HOLES ! 2 Trolls, both from the basement.
     
  8. anonymous

    anonymous Guest

    There's much more going on, far beyond Google and Dexcom. The biggest drivers are software and data companies, where the real money will be made. Next comes the wearable component, which is all about fashion and micro electronics. Think Apple, Samsung, Phillips, Nike, Bose, etc. Dozens in on that. The commodity is the actual implant, which is the only place a traditional pharma company can play. Low margin, not Abbott's game. That part is low cost bid wins; this is all China, high tech 99% robotics, and low margin high volume.

    As for ADC or even Abbott making a deal? That starts with knowing who to talk to, and being able to even start a dialog. Then of course having something to offer besides "hello". Forget it. Just the sounds of crickets.
     
  9. anonymous

    anonymous Guest

    It takes time to get these products out. ADC used what was new technology at the time (2009), developed, made it, and got approvals. All companies in this regulated industry need to do this...Google will find out soon enough. The problem with ADC is follow through....no real plan for the next big idea and no money to do it anyway.

    Need to keep ahead of the curve and big pharma has trouble doing this in the device market. That is why a partnership between a tech company and device company could make the difference. DexCom and Google could do this...DexCom is in San Diego and so is one of the hot new sensors (UCSD). Bet Google will write a big check and bring this technology in under their umbrella.

    Good for the user.....bad for Abbott.
     
  10. anonymous

    anonymous Guest


    And here it comes:



    http://www.fiercemedicaldevices.com/story/fda-approves-first-self-contained-mobile-continuous-blood-glucose-monitor-d/2015-08-25
     
  11. anonymous

    anonymous Guest

    Now THIS is wave 1 of the future, the first in a new generation of easy to apply, inexpensive technology that will work with any of the many apps that will be developed. All open coded. The winners here will be the software and systems developers who create the tools doctors and hospitals will be able to use to monitor patients, seamlessly integrating all this data into patient records. HCP's will not only be able to see how their patients are doing with zero effort by the patient, but will also be alerted to patterns and other concerns, and can then reach out to patients.

    Dolts and dinosaurs like Abbott are not only NOT in the game; they haven't a clue WHAT the game even is. Abbott will insist on developing its own expensive and stand alone devices, software, and apps, because they will NEVER do ANYTHING open source. That mind set alone ensures ADC and Abbott will remain where it is today: on the outside, standing in the cold rain ... and NOT looking in, as the old saying goes, because they don't know WHERE to look.
     
  12. anonymous

    anonymous Guest

    OMG WTF ? Y'all are STILL arguing over that dog product called Libre ?
     
  13. anonymous

    anonymous Guest

    Abbott is in the game because nobody has anything NOW as good as Libre. Abbott is a starter of the game. And they will play the game for a while but they will lose due to the nature of the company. Other companies will still play and the true winners are the patients who need this technology to improve their lives. End game.
     
  14. anonymous

    anonymous Guest

    Abbott isn't losing Nothing ! A POS glucose meter isn't Abbotts bread and butter Y'all is So narrow minded
     
  15. anonymous

    anonymous Guest

    Don't talk about the game, when y'all aren't even in the Arena, let alone the "game"
     
  16. anonymous

    anonymous Guest

    And that, sir ,is the problem with Abbott. It has so many products and ways of making money it can't focus on one thing. I worked at Abbott for 13 years....a very good company. But due to it's size Abbott finds it difficult to do new things. That's why Miles is always buying innovation by taking over smaller companies.
     
  17. anonymous

    anonymous Guest

    Is Abbott selling Libra? It doesn't even have FDA approval. The EU program is a subsidized test. Abbot has nothing now. To further expose why you are the poster child for why Abbot does not even know what that game is, the game will not involve a meter as we know it today. Abbott is showing up with helmut and pads to a swim meet.

    Next?
     
  18. anonymous

    anonymous Guest

    Correct. Abbott isn't losing. It's selling out. Or had been trying to ADC has been on the block for years. But no takers.
     
  19. anonymous

    anonymous Guest

    Bullshit.
     
  20. anonymous

    anonymous Guest

    Very good answer! Well argued, fact-based, and persuasive. And they say ADC senior management is a bunch of simpletons! You sir or madam (or other; hey this is ADC after all) are a credit to Abbott mgt selection and training.